GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

A week after announcing plans to boost its late-stage pipeline with the £1.5bn acquisition of Sierra Oncology (NASDAQ:SRRA), GlaxoSmithKline PLC (LSE:GSK) has unveiled some home-grown success. It said the US Food & Drug Administration has accepted a new drug application for daprodustat for people with chronic kidney disease that also suffer anaemia.

GlaxoSmithKline new drug application for specialist anaemia treatment

Open Text

Pfizer

Taiwan Semiconductor Manufacturing

Unilever

One strategy that investors can use to search for potential value opportunities is to screen the market for stocks with a history of solid profitability and shareholder returns that are trading near their 52-week lows. While past results are not a guarantee of future performance, companies with a proven track record can often provide more stability than those that have yet to turn a profit.

5 Predictable Stocks Trading Near 52-Week Lows

Rite Aid

Health care stocks are making the rounds as the pandemic continues to pose challenges globally and high growth names lose steam.

Best Stocks To Buy Right Now? 3 Health Care Stocks In Focus

We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates for a potential takeover in 2022.

M&As in Spotlight With GSK Announcement: 3 Biotechs in Focus

GlaxoSmithKline's anemia of chronic kidney disease drug could be just months away from authorization in the European Union.

Here's What This Regulatory News Could Mean for GlaxoSmithKline

Sierra Oncology

NEW YORK , April 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sierra Oncology, Inc. ("Sierra" or the "Company") (NASDAQ: SRRA), in connection with the proposed acquisition of the Company by GlaxoSmithKline plc (NYSE: GSK).  Under the terms of the merger agreement, the Company's shareholders will receive $55.00 in cash for each share of Sierra common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates Sierra Oncology, Inc.

Sierra Oncology (NASDAQ: SRRA) shares traded significantly higher after announcing the acquisition by GlaxoSmithKline PLC (LON: GSK) for $55 a share in cash. That represents a total equity value of $1.9 billion, attributed mainly to SRRA's Momelotinib, a differentiated mode of action with inhibitory activity and critical signalling pathways.

Late-Stage Biopharmaceutical Sierra Oncology announces acquisition by GSK

The acquisition of Sierra Oncology (SRRA) will add late-stage oncology pipeline candidate, momelotinib to Glaxo's (GSK) hematology pipeline.

Glaxo (GSK) to Buy Sierra for $1.9B, Add Hematology Drug

Shares of Sierra Oncology Inc. SRRA, +3.10% soared 37.3% in premarket trading on Wednesday after GlaxoSmithKline GSK, +0.11% GSK, +0.63% said it would buy the company for $1.9 billion. Sierra is developing treatments for rare types of cancer, including myelofibrosis, and announced in January that momelotinib met the primary and secondary endpoints in a Phase 3 clinical trial evaluating the experimental therapy as a treatment for myelofibrosis.

GlaxoSmithKline to buy Sierra Oncology for $1.9 billion

The deal comes ahead of GlaxoSmithKline's planned spinoff of its consumer health division in July.

Sierra Oncology Soars After Takeover by Glaxo

GlaxoSmithKline plc (NYSE: GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ: SRRA) for $55 per share in cash, representing an approximate total equity value of $1.9 billion (£1.5 billion). Sierra's momelotinib complements GSK's Blenrep (belantamab.

GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal

GlaxoSmithKline plc (NYSE: GSK) announced it is buying Sierra Oncology, Inc (Nasdaq: SRRA) for $1.9 billion (£1.5 billion). These are the details.

Why GlaxoSmithKline (GSK) Is Buying Sierra Oncology (SRRA) For $1.9 Billion

Sierra Oncology Stock Soars After $1.9 Billion Takeover by GlaxoSmithKline

Pharmaceutical giant GlaxoSmithKline PLC said Wednesday that it is buying biopharmaceutical company Sierra Oncology Inc. for $1.9 billion, and backed its guidance.

GlaxoSmithKline to buy Sierra Oncology for $1.9 billion.

It is the fate of the small(er) drug developer – to be taken out just when all the hard yards have been put in. And it's exactly what's happened to Nasdaq-listed Sierra Oncology (NASDAQ:SRRA).

GlaxoSmithKline boosts its oncology product line as it swoops for American drug developer in US$1.9bn deal

Britain's GlaxoSmithKline has agreed to buy California-based biopharmaceutical company Sierra Oncology in a deal valued at $1.9 billion, the companies said on Wednesday.

GSK to buy Sierra Oncology for $1.9 billion

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Sierra Oncology, Inc (Nasdaq: SRRA) today announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $55 per share of common stock in cash representing an approximate total equity value of $1.9 billion (£1.5 billion). Myelofibrosis is a fatal cancer of

GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn

AstraZeneca

Johnson & Johnson

Eli Lilly

Merck

Moderna

Do results from an important clinical trial affect the stock price of pharma companies? We're about to find out, as several readouts are expected in the second quarter.

Will These Pharma Giants Pop or Flop on Clinical Study Readouts?

CureVac B.V

Shares of CureVac CVAC, -0.28% were up 0.6% in premarket trading on Monday after the company and GlaxoSmithKline GSK, +0.89% said they signed an agreement with the German government for pandemic preparedness that includes mRNA vaccines. As part of the agreement, Germany has access to CureVac's mRNA manufacturing until 2029.

CureVac, GSK ink 'pandemic preparedness' agreement through 2029 with German government

Regeneron Pharmaceuticals

Vir Biotechnology

With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a lack of efficacy against the same.

Antibody Treatments for COVD-19 Face Challenges in the U.S.

GlaxoSmithKline's GSK, +1.87% IV drug for COVID-19 should no longer be used because it is likely ineffective against the omicron subvariant that now accounts for most U.S. cases, federal health regulators said Tuesday, the Associated Press reported. That leaves just one antibody treatment that is still authorized for use, an Eli Lilly LLY, +0.37% drug that still sees effective, after another Eli Lilly drug and one from Regeneron REGN, -0.99% were deemed ineffective.

Coronvirus tally: FDA pulls Glaxo COVID treatment ahead of panel meeting on next steps for 2022

Axsome Therapeutics

Immunocore Holdings

Looking for a healthcare stock with strong leadership? Our roundtable likes Immunocore, Axsome Therapeutics, and GlaxoSmithKline.

3 CEOs to Invest In

First Trust Nasdaq Pharmaceuticals ETF 

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

Sanofi

SPDR S&P Pharmaceuticals ETF

The pending separation of consumer care businesses by pharmaceutical companies is understandable and may offer investment opportunities.

Pharma In Transition: Context And Opportunities

The FDA restricts the use of sotrovimab, Glaxo (GSK)/Vir's (VIR) COVID therapy, in several states and territories based on the latest data that does not support the therapy's effectiveness against a dominating Omicron subvariant.

FDA Revises EUA of Glaxo (GSK) & Vir's (VIR) COVID Therapy

The FDA said that the currently authorized 500mg dose of GlaxoSmithKline Plc (NYSE: GSK) and Vir Biotechnology Inc's (NASDAQ: VIR) COVID-19 antibody therapy is unlikely to be effective against the omicron BA.2 variant. The agency updated its website to exclude.

FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant

News for GlaxoSmithKline Stock (GSK)